Four Innovative Drugs Empower the Treatment of Myasthenia Gravis, Opening a New Era of Precision Diagnosis and Treatment

Generic Name

English Generic Name

Trade Name

Research and Development Enterprise

Core Mechanism of Action

Clinical Advantages

Telitacicept

Telitacicept

Tai'ai

Rongchang Bio

The world's first APRIL/BLyS dual-target antagonist (fully human TACI-Fc fusion protein), which simultaneously blocks BLyS and APRIL targets, inhibiting the maturation of autoreactive B cells and the secretion of autoantibodies.

1.  Excellent efficacy, with a response rate of 98.1% for MG-ADL score reduction ≥ 3 points;

2.  Included in medical insurance, with an annual cost of only 60% of similar drugs in the medical insurance catalog, featuring high cost-effectiveness;

3.  Subcutaneous injection once a week, which can be completed in outpatient clinics, with a fixed dose without weight calculation;

4.  Obtained FDA and EU orphan drug designation and fast track qualification.

Rozanolixizumab Injection

Rozanolixizumab Injection

Youdige (Uzedy)

UCB

A humanized IgG4 monoclonal antibody that specifically binds to FcRn receptors to rapidly and efficiently clear pathogenic antibodies in the body, with extremely high affinity in both acidic and neutral environments.

1.  Covers both acetylcholine receptor antibody-positive (AChR Ab+) and muscle-specific receptor tyrosine kinase antibody-positive (MuSK Ab+) patients with generalized myasthenia gravis, breaking the dilemma of no available drugs for MuSK Ab+ myasthenia gravis;

2.  Clinical response rate of 100%, with safety similar to placebo;

3.  Only 2.9 treatment cycles are needed annually, greatly reducing the frequency of medical visits;

4.  Fills the gap in medical insurance for MuSK Ab+ myasthenia gravis and is recommended by multiple domestic and foreign authoritative guidelines.

Zilucoplan Sodium Injection

Zilucoplan Sodium

Zhuobeike (Zilbrysq)

UCB Pharma

A new generation of C5 complement inhibitor with dual inhibitory effects, which can be administered subcutaneously and self-administered, specifically for the treatment of adult patients with generalized myasthenia gravis who are AChR antibody-positive, by targeting and inhibiting complement-mediated neuromuscular junction damage.

1.  Rapid onset of action, which can significantly improve patients' functions such as breathing, swallowing and speaking within 1 week;

2.  Can be self-administered at home, with subcutaneous injection completed in 5-8 seconds, featuring high convenience;

3.  Reduces dependence on intravenous immunoglobulin (IVIg) and plasma exchange (PE), with mild common adverse reactions and good tolerance.

Ravulizumab Injection

Ravulizumab Injection

Weilirui (Ultomiris)

AstraZeneca (Alexion Pharmaceuticals)

A long-acting humanized C5 complement monoclonal antibody that binds to the key complement system protein C5 with high affinity, blocking its cleavage into C5a and C5b and inhibiting the formation of membrane attack complex (MAC), thereby curbing tissue damage caused by abnormal complement activation from the source.

1.  Long-acting and durable, with intravenous injection once every 8 weeks after the initial induction dose, only 6 treatments per year;

2.  Treatment adherence is improved by more than 60%, suitable for moderate to severe myasthenia gravis patients with mobility impairments;

3.  Efficacy lasts up to 164 weeks, and the incidence of disease exacerbation per 100 patients per year is reduced by 71.1%;

4.  Covers two neuroimmune rare disease indications.